STCube

STCube CROIC

The Cash Return on Invested Capital (CROIC) of STCube (052020.KQ) as of Oct 24, 2026 is -28.71 %. In the previous year, Cash Return on Invested Capital (CROIC) was -22.94 % — a change of 25.12% (lower).

CROIC

-28.71 %

YoY

25.12%

Last updated:

Cash Return on Invested Capital (CROIC) of STCube is 2025 -28.71 % . Cash Return on Invested Capital (CROIC) of STCube was 2024 -22.94 % . It decreases by 25.12% lower compared to the previous year.

The STCube CROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CROIC
Date
CROIC
Jan 1, 2018
-12.69 KRW
Jan 1, 2019
-3.05 KRW
Jan 1, 2020
-25.40 KRW
Jan 1, 2021
-86.13 KRW
Jan 1, 2022
-30.67 KRW
Jan 1, 2023
-67.16 KRW
Jan 1, 2024
-22.94 KRW
Jan 1, 2025
-28.71 KRW
The STCube CROIC history
YEARCROICYoY
-28.71 %+25.12%
-22.94 %-65.84%
-67.16 %+118.98%
-30.67 %-64.39%
-86.13 %+239.07%
-25.40 %+732.25%
-3.05 %-75.95%
-12.69 %-79.47%
-61.80 %+3,268.89%
-1.83 %-94.90%
-35.97 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Cash Return on Invested Capital (CROIC) of STCube is -28.71 % in 2025.

Cash Return on Invested Capital (CROIC) of STCube changed from -22.94 % to -28.71 %, representing a 25.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Return on Invested Capital (CROIC) STCube since 2006 – with annual values, charts, and detailed analysis.

CROIC measures the cash return generated on invested capital. Unlike ROIC, it uses free cash flow instead of accounting earnings, providing a purer profitability measure.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Return on Invested Capital (CROIC)'s STCube with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Return on Invested Capital (CROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Return on Invested Capital (CROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — STCube

All Key Metrics — STCube